

1 Integrated multi-omics reveals anaplerotic rewiring 2 in methylmalonyl-CoA mutase deficiency

3
4 Patrick Forny^{1a}, Ximena Bonilla^{2a}, David Lamparter^{3,8a}, Wenguang Shao^{4,8a}, Tanja Plessl¹, Caroline
5 Frei¹, Anna Bingisser¹, Sandra Goetze^{4,8}, Audrey van Drogen^{4,8}, Keith Harshman^{3,8}, Patrick G. A.
6 Pedrioli^{4,8}, Cedric Howald³, Florian Traversi¹, Sarah Cherkaoui¹, Raphael J. Morscher¹, Luke
7 Simmons⁵, Merima Forny¹, Ioannis Xenarios^{6,8}, Ruedi Aebersold^{7,8}, Nicola Zamboni^{7,8}, Gunnar
8 Rättsch², Emmanouil Dermitzakis^{3,8}, Bernd Wollscheid^{4,8*}, Matthias R. Baumgartner^{1*}, D. Sean
9 Froese^{1*}

10
11 ¹ Division of Metabolism, University Children's Hospital Zurich, University of Zurich, Switzerland

12 ² Biomedical Informatics, Department of Computer Science, Swiss Federal Institute of Technology /
13 ETH Zürich, Switzerland

14 ³ Health 2030 Genome Center, Geneva, Switzerland

15 ⁴ Institute of Translational Medicine, Department of Health Science and Technology, Swiss Federal
16 institute of Technology / ETH Zürich, Switzerland

17 ⁵ Division of Child Neurology, University Children's Hospital Zurich, University of Zurich,
18 Switzerland

19 ⁶ Agora Center, Rue du Bugnon 21, Lausanne, Switzerland

20 ⁷ Institute of Molecular Systems Biology, Department of Biology, Swiss Federal Institute of
21 Technology / ETH Zürich, Switzerland

22 ⁸ PHRT Swiss Multi-OMICS Center / smoc.ethz.ch, Switzerland

23
24 ^a These authors contributed equally to this study.

25 * Correspondence: sean.froese@kispi.uzh.ch (Lead Contact), matthias.baumgartner@kispi.uzh.ch,
26 bernd.wollscheid@hest.ethz.ch

29 **Abstract**

30 Multi-layered omics technologies can help define relationships between genetic factors, biochemical
31 processes and phenotypes thus extending research of monogenic diseases beyond identifying their
32 cause. We implemented a multi-layered omics approach for the inherited metabolic disorder
33 methylmalonic aciduria. We performed whole genome sequencing, transcriptomic sequencing, and
34 mass spectrometry-based proteotyping from matched primary fibroblast samples of 230 individuals
35 (210 affected, 20 controls) and related the molecular data to 105 phenotypic features. Integrative
36 analysis identified a molecular diagnosis for 84% (179/210) of affected individuals, the majority (150)
37 of whom had pathogenic variants in methylmalonyl-CoA mutase (*MMUT*). Untargeted integration of
38 all three omics layers revealed dysregulation of TCA cycle and surrounding metabolic pathways, a
39 finding that was further supported by multi-organ metabolomics of a hemizygous *Mmut* mouse model.
40 Stratification by phenotypic severity indicated downregulation of oxoglutarate dehydrogenase and
41 upregulation of glutamate dehydrogenase in disease. This was supported by metabolomics and isotope
42 tracing studies which showed increased glutamine-derived anaplerosis. We further identified MMUT
43 to physically interact with both, oxoglutarate dehydrogenase and glutamate dehydrogenase providing
44 a mechanistic link. This study emphasizes the utility of a multi-modal omics approach to investigate
45 metabolic diseases and highlights glutamine anaplerosis as a potential therapeutic intervention point
46 in methylmalonic aciduria.

47


48

49 **Take home message:** Forny et al. have combined integrative multi-omics with clinical and
50 biochemical features and demonstrate an increased diagnostic rate compared to genome sequencing
51 alone and the identification of anaplerotic rewiring as a potentially therapeutically targetable feature
52 of the rare inborn error of metabolism methylmalonic aciduria.

53

54

55 Graphical abstract



56

57

58 Keywords

59 Rare disease, inborn error of metabolism, multi-omics, RNA-seq, WGS, proteomics, methylmalonic
60 aciduria

61

62 **Main**

63 Inborn errors of metabolism (IEMs), first described by Archibald Garrod (Garrod, 1908), are inherited
64 diseases resulting in inadequate function of metabolic proteins. IEMs represent a group of nearly 1500
65 diseases with a combined incidence of approximately 1:800 births. They present a clinically and
66 genetically heterogeneous picture making them inherently difficult to diagnose (Ferreira et al., 2021;
67 Rahman, 2020). Beyond their diagnostic challenges, the pathomechanisms of many IEMs are not well
68 understood, hence most IEMs lack rationalized treatment approaches (Hirano et al., 2018).

69 Technological advances in genomics and mass spectrometry, leveraging datasets of whole molecule
70 classes (omics), have recently led to a paradigm shift in their use as diagnostic tools. For example,
71 single-layer whole genome sequencing has achieved diagnostic rates of 30-50% (Palmer et al., 2021;
72 Schon et al., 2021), while dual-layer combination with RNA sequencing can improve this by 10-35%
73 (Cummings et al., 2017; Frésard et al., 2019; Gonorazky et al., 2019; Kremer et al., 2017). In spite of
74 these advances a significant number of patients remain undiagnosed and course prediction also
75 remains poor, mainly due to a lack of pathomechanistic understanding and often unclear
76 genotype/phenotype relationships.

77 Multi-layered omics data have the potential to not only increase diagnosis rates of inborn errors of
78 metabolism, but also to uncover novel mechanistic insights into disease pathophysiology (Argmann et
79 al., 2016), thus potentially indicating new therapeutic targets. Such an approach is key to move
80 beyond the traditional “one gene – one disease” view of these disorders which fails to explain
81 phenotypic heterogeneity based on genetic variation only.

82 Here, we have generated multi-layered omics information from individuals suspected with the
83 prototypic IEM methylmalonic aciduria (MMA). MMA has approximately 20 potential monogenic
84 causes most of which result in deficiency of the methylmalonyl-CoA mutase (MMUT) enzyme due to
85 loss of function or proper cofactor assembly. Even though the position of MMUT as an anaplerotic
86 tricarboxylic acid (TCA) cycle enzyme producing succinyl-CoA from methylmalonyl-CoA is well
87 known, the main metabolic disturbances in MMA remain an open question.

88 By combining WGS, RNA-seq, and DIA-MS derived proteotype information with phenotypic
89 features we identified disease causative and pathogenic features in a cohort of MMA affected
90 individuals. These revealed differentially expressed transcripts and proteins directly related to
91 anaplerosis of the TCA cycle. Moreover, follow-up studies utilizing untargeted metabolomics and
92 [¹³C]glutamine tracing identified a shift from reductive to oxidative TCA cycling for glutamine
93 derived metabolites due to dysregulation of glutamate dehydrogenase and oxoglutarate dehydrogenase
94 enzymes, which we found to physically interact with MMUT. These may be compensation and
95 potential intervention points in MMA.

96

97 **Results**

98 Monogenic disease variant detection through multi-omics

99 To extend the understanding of MMA from the causative genomic lesions to the affected biochemical
100 processes, we performed WGS, RNA-seq and DIA-MS based proteotyping on fibroblasts taken from
101 230 individuals (210 affected by MMA, 20 unaffected), representing a mainly European cohort
102 collected over a 25-year period (**Fig. 1a** and **Extended data Fig. 1a**). Overall quality assurance tests
103 revealed a mean of high quality aligned genomic reads of 8.7×10^8 at a median genomic coverage of
104 >38 -fold (**Extended data Fig. 1b**). A median of 3.74 million SNVs were called using the Genome
105 Analysis Toolkit (McKenna et al., 2010) and DeepVariant (Poplin et al., 2018). RNA-seq data showed
106 a median Phred score of >36.3 at three and more cycles (**Extended data Fig. 1c**), while proteomics
107 data showed a high reproducibility with 2218 proteins detected in at least 75% of samples (**Extended**
108 **data Fig. 1d**). For nine of the 230 samples RNA extraction yielded insufficient nucleic acid amounts
109 to proceed with transcriptome sequencing; hence, these datasets were excluded from all further
110 analysis (transcriptomics data of sample IDs 22, 54, 59, 78, 89, 109, 123, 207, 221).

111 MMA is caused by defective processing of methylmalonyl-CoA – a product of propionyl-CoA
112 catabolism and an anaplerotic substrate of the TCA cycle – resulting from deficiency of the enzyme
113 methylmalonyl-CoA mutase (MMUT) or proteins related to production of its cofactor
114 (adenosylcobalamin) or substrate (**Fig. 1a**). Biochemical assay of propionyl-CoA catabolism (PI)
115 (Froese and Baumgartner, 2020), and MMUT enzyme activity (Forny et al., 2014) strongly correlated
116 across all samples ($r=0.73$, $p<0.0001$) (**Extended data Fig. 2a**). Fibroblasts from 150 individuals with
117 MMA had reduced MMUT activity, including 123 which did not increase upon cofactor
118 supplementation (**Extended data Fig. 2b, c**), while those of 60 individuals had MMUT activity
119 similar to controls (**Fig. 1b, Extended data Table 2**). Those with reduced MMUT activity were
120 designated as MMUT-deficient, the others were designated as MMA affected individuals with
121 unknown cause.


122 In the MMUT-deficient samples we searched for disease causing variations in the *MMUT* gene and
123 identified a bi-allelic molecular diagnosis in 148/150 individuals (**Extended data Table 1**).

124 Pathogenic variants constituted 165 missense alleles, 105 truncating alleles, 21 splicing alleles, two
125 alleles with in-frame deletions and three alleles containing copy number variants (**Fig. 1c, d** and
126 **Extended data Fig. 2d**), of which 41 variants were novel (**Extended data Table 1**). RNA-seq
127 identified reduced *MMUT* RNA expression in cells from MMUT-deficient individuals compared to
128 the other groups (**Fig. 1e**). Individuals with strongly reduced RNA expression were enriched for
129 splicing and/or truncating variants, consistent with nonsense mediated decay (**Extended data Fig.**
130 **2e**). DIA-MS based proteome measurements revealed reduced MMUT protein levels in MMUT-
131 deficient cell lines (**Fig. 1f**) which was distributed across all variant types (**Extended data Fig. 2e**).

132 Consistent with its disease-causing role, MMUT RNA and protein levels were positively and
133 significantly associated with PI and MMUT activity (**Extended data Fig. 2f**) and MMUT represented
134 the most significantly dysregulated RNA and protein of MMUT-deficient samples when compared
135 against all other samples (**Fig. 1g** and **Extended data Fig 2g**).

136 In the 60 unknown samples, we identified bi-allelic disease-causing variants in *ACSF3* (17
137 individuals) (**Fig. 1h**), *TCN2* (3 individuals), *SUCLA2* (1 individual) and *MMAB* (1 individual)
138 (**Extended data Table 1**). By searching RNA-seq for aberrantly expressed genes using OUTRIDER
139 (Brechtmann et al., 2018) (**Extended data Fig 3**), we identified two individuals with very low *ACSF3*
140 expression; two with aberrant *SUCLA2* expression, in whom we confirmed predicted splicing and
141 copy number variants at the genomic level (**Extended data Table 1**); two with very low *MMAA*
142 expression, confirmed by complementation analysis; and one with low *MMAB* transcript, also
143 confirmed by complementation analysis. Therefore, we identified a molecular cause for 29/60
144 remaining individuals, including 18 pathogenic mutations, of which 10 were novel (**Extended data**
145 **Table 1**). In sum, we found a diagnosis for 177/210 (84%) affected individuals (**Fig. 1i**), including
146 150 with deficiency of MMUT and 19 of *ACSF3*, the largest cohort of *ACSF3* individuals so far
147 described.

148



149

150 **Fig. 1: Multi-faceted omics view enables a molecular diagnosis in 84% of individuals.** **a**, Study
 151 overview with depiction of the propionate pathway including its precursors and the pathways
 152 catalyzed by MMUT. **b**, MMUT enzyme activity per study sub-cohort. **c**, Lollipop plot of all
 153 pathogenic variants found on the *MMUT* gene. **d**, Proportions of variant types as identified on the
 154 *MMUT* gene. **e**, Transcript levels of MMUT divided in study sub-cohorts. **f**, MMUT protein levels
 155 divided in study sub-cohorts. **g**, Gene ranks according to p-values as calculated by gene-wise Welch's
 156 *t*-test in the proteomics and transcriptomics data. **h**, Lollipop plot of pathogenic variants identified in
 157 *ACSF3*. **i**, Proportions of affected genes identified in the whole cohort.

158

159 Phenotypic description and association to disease severity

160 A correlation matrix of all continuous numeric variables as well as discrete phenotypic variables ($n =$
 161 105), spanning clinical symptoms at presentation and during disease course ($n = 53$), clinical
 162 treatments required and response ($n = 23$), clinical chemistry of blood or tissues including metabolite
 163 measurements ($n = 13$), and *in vitro* biochemical parameters ($n = 13$), revealed a cluster of


164 biochemical parameters (MMUT activity, PI) that showed strong correlation across many variables
165 (**Fig. 2a, b**).

166 Since these few variables strongly associated to many clinical features, we postulated that most
167 disease characteristics might be well predicted by one or a select few variables. As proof-of-principle,
168 we established a clinical severity score (CSS), which incorporated the outcome of five typical clinical
169 features ((Forny et al., 2021), for composition see **Methods**), whereby a score of 0 represented
170 asymptomatic individuals, 1 mild disease, and score 2 or higher moderate to severe disease.

171 Comparison of the CSS against all phenotypic parameters demonstrated significant correlation with
172 54 individual variables (**Fig. 2c**), including many classical phenotypic symptoms of MMAuria, such
173 as acidosis, hyperammonemia and muscular hypotonia as well as the requirement for dietary and
174 pharmacological interventions (**Extended data Fig. 4a**). Importantly, the CSS also inversely
175 correlated with age of onset (**Extended data Fig. 4b**), a parameter that on its own has been used as an
176 indication of clinical severity (Hörster et al., 2009).

177 Multiple correlation analysis identified PI in the presence of hydroxocobalamin (PI+) to significantly
178 correlate to 41 phenotypic features, the most of any individual continuous variable (**Fig. 2c**). This
179 contrasts, for example, to age at onset which significantly correlated with only 17 parameters (**Fig.**
180 **2c**). Closer inspection revealed PI+ to be inversely related to disease severity, including significant
181 correlation with e.g. glomerular filtration rate, age at disease onset, methylmalonic acid concentration
182 in plasma, presence of clinical interventions such as protein restriction and the CSS (**Fig. 2d** and
183 **Extended data Fig. 4c,d**). Therefore, we used PI+ as an approximation of clinical disease severity in
184 this study.

185



186

187 **Fig. 2: Phenomics analysis reveals two main surrogate markers of disease severity (clinical**
188 **severity score and PI+ activity).** **a**, Correlation matrix of all continuous numeric and discrete
189 phenotype variables. **b**, Number of phenotypic traits according to five phenotype subcategories. **c**,
190 Panel of selected phenotypic traits and their overall strength of representing the entirety of the
191 phenomics dataset (here termed clinical disease severity) as assessed by linear modelling. Each point
192 represents the result of linear regression against one other phenotypic variable with the effect size on
193 the y-axis and the resulting p-value on the x-axis. The horizontal curved line indicates the density of
194 data points as distributed along the x-axis. Vertical dashed line indicates threshold of significance (p-
195 value <0.05). **d**, Linear regression results of the PI+ activity variable compared against the rest of the
196 phenotypic variables.

197

198 Multi-layered biology reveals disruption of TCA cycle and associated pathways

199 To identify disease-associated expression alterations of genes, proteins, and pathways, we attempted
200 global assessment of transcript and protein expression. Since patients with TCN2, SUCLA2 and
201 ACSF3 deficiency do not show typical signs and symptoms of classical MMA, we compared MMUT-
202 deficient (150 samples) with all non-MMUT-deficient samples (control, 80 samples).

203 Investigation of transcripts and proteins using differential correlation patterns (Pearson correlation
204 method), dimensionality reduction via Principal Component Analysis and DESeq2 did not
205 immediately yield clear grouping of the data, nor obvious expression pattern differences between the
206 groups (**Extended data Fig. 5a, b, c**). However, multi-omics factor analysis (Argelaguet et al., 2018),
207 integrating both genetic data layers and proteotyping data, identified mitochondrial metabolic
208 pathways and in particular the electron transport chain and the TCA cycle to be enriched in MMUT-
209 deficient samples (**Fig. 3a**). In more detail, the proteins SLC16A3, CS, MDH2, and OGDH were
210 found to be the main drivers of this particular factor variance in the proteotyping data within the TCA-
211 associated gene sets (**Fig. 3b**). Linear discriminant analysis of genes shared between transcriptomics
212 and proteotyping indicated MMUT as the strongest and SUCLA2, OGDH and PDHB to be top drivers
213 of separation between MMUT-deficient and control samples (**Fig. 3c**).


214 Further, gene set enrichment analysis utilizing sample stratification by disease severity, both by CSS
215 and PI+, also identified oxidative phosphorylation and the TCA cycle as over-represented pathways in
216 the proteomics (CSS and PI+) and transcriptomics (CSS) datasets (**Fig. 3d**). Within the underlying
217 differential expression analysis, performed using a linear mixed modelling approach (Lamparter et al.,
218 2017), genes in the proteomics dataset that had an effect size $|\gt;0.2|$ and were significantly (p -value $<$
219 0.01) enriched for mitochondrial localization, as listed in MitoCarta 3.0 (Rath et al., 2021) (**Fig. 3e**).

220 Closer examination identified MMUT to be significantly downregulated in disease at both the RNA
221 and protein level, while ALDH2, which catalyzes the interchange between methylmalonate and
222 methylmalonate semialdehyde, was upregulated in both (**Fig. 3f, g**). A further upregulated transcript
223 was PDK4 (**Fig. 3g**), which is responsible for the phosphorylation and as a consequence inactivation
224 of the pyruvate dehydrogenase complex. However, the proteins with the overall largest effect size
225 were OGDH (downregulated in disease) and GLUD1 (upregulated in disease) (**Fig. 3f**).

226 The biological relevance of these changes were confirmed in a hemizygous mouse model of MMUT-
227 deficiency (Forny et al., 2016) (**Fig. 3h**). Untargeted metabolomics of brain, heart, kidney, liver,
228 plasma and urine confirmed elevated levels of the eponymous metabolite methylmalonic acid in
229 mutant animals, while pathway analysis identified significantly dysregulated TCA cycle pathways in

230 all tissues and urine (**Fig. 3i**). Transcriptomics of brain tissue further confirmed the expected 50%
 231 reduction in *Mmut* transcript of mutant mice, along with enrichment of electron transport chain and
 232 oxidative phosphorylation pathways (**Fig. 3j** and **Extended data Fig. 6**).

233



234

235 **Fig. 3: Untargeted inspection of omics data layers highlights TCA cycle and associated**

236 **pathways as well as oxidative phosphorylation gene sets to be dysregulated in MMA. a**, Gene set
 237 enrichment test using the multi-omics factor analysis as previously published (Argelaguet et al.,
 238 2018). **b**, Detailed feature statistics of the top enriched gene sets following multi-omics factor analysis
 239 in the proteomics data. **c**, Linear discriminant model (split to assign training and test data: 0.5) of
 240 transcripts separates *MMUT*-deficient from control driven by *MMUT* and other genes related to the

241 TCA cycle. **d**, Gene set enrichment analysis based on effect size ranking derived from differential
242 expression analysis using sample stratification based on the clinical severity score or PI activity. **e**,
243 Proportions of proteins localized to the mitochondria (according to MitoCarta 3.0) split according to
244 the result of the differential expression analysis. The splits are indicated by dashed horizontal and
245 vertical lines in (f) and (g). **f**, Q-Q and volcano plots illustrating the results of the differential
246 expression analysis based on a linear mixed modelling approach according to (Lamparter et al., 2017)
247 applied to the proteomics data, restricted to enzymes (or their encoding genes) localized in the
248 mitochondria. **g**, Same as (F) but for transcriptomics data. **h**, Breeding scheme of *Mmut* deficient mice
249 (Forny et al., 2016). **i**, Untargeted metabolomics in mouse tissues and body fluids, depicting boxplots
250 for methylmalonic acid and gene set enrichment analysis results. **j**, RNA-seq on mouse brain tissue.
251 Boxplots of the relative *Mmut* transcript abundance and gene set enrichment analysis following
252 DESeq2 analysis, dot size represents number of genes per set.

253


254 MMUT deficiency leads to transcript and protein alterations in proximal
255 enzymes

256 Since both, data-driven and clinically stratified analyses indicated TCA and associated pathways to be
257 disrupted in disease, we performed concerted investigation of TCA cycle anaplerotic and cataplerotic
258 enzymes from which we had both RNA and protein information. As controls we included isoforms of
259 TCA enzymes which are not involved in these pathways (**Fig. 4a**). Direct comparison of RNA and
260 protein expression between MMUT-deficient and control cells revealed only MMUT to be
261 significantly dysregulated (**Fig. 4a outer band**). However, differential expression analysis, performed
262 analogous to **Fig. 3f, g**, indicated RNA expression of *SUCLA2* to be upregulated with increased
263 disease severity, while protein expression of *OGDH* and *SUCLA2* were reduced and *GLUD1*
264 increased in disease; *MMUT* RNA and proteins levels were downregulated in disease as expected
265 (**Fig. 4a middle band**).

266 Examination of RNA-protein expression correlation in all samples revealed a limited Spearman
267 correlation of 0.14 at the gene level (4318 transcript-protein pairs) and 0.40 at the sample level (**Fig.**
268 **4b** and **Extended data Fig. 7a**), similar to findings by others (Nusinow et al., 2020). Comparison of
269 RNA-protein correlation in MMUT-deficient cells compared to controls revealed that, while 1158
270 pairs (26.8%) correlated significantly (p -value < 0.05) in both genotypes (**Fig. 4c** all colored points
271 and **Extended data Fig. 7b**) in accordance with previous studies (Williams et al., 2016), the
272 correlation of some genes segregated depending on the genotype (MMUT-deficient vs control) (**Fig.**
273 **4c**). In particular, OGDH, GLUD1, CS and GLS showed higher RNA-protein correlation in MMUT-
274 deficient samples than controls, while SUCLA2 had reduced RNA-protein correlation (**Fig. 4a, c** and
275 **Extended data Fig. 7c**). OGDH and SUCLA2 were among the genes with the strongest genotype-
276 dependent RNA-protein correlation changes (**Fig. 4c**). Interestingly, we found poor RNA-protein
277 correlation for MMUT in both control and MMUT-deficient cells (**Fig. 4a, c** and **Extended data Fig.**
278 **7c**).

279 Finally, MMUT protein levels positively correlated to protein levels of many TCA and anaplerotic
280 enzymes in control but not MMUT-deficient cells, while there was little or no protein expression
281 correlation between MMUT and non-TCA protein isoforms in either genotype (**Fig. 4a center** and
282 **Extended data Fig. 7d**). Such a relationship is exemplified by MMUT:ACO2 and MMUT:ACO1
283 (**Fig. 4a center** and **Extended data Fig. 7e**) and provides the first indication that MMUT may be part
284 of an interaction network with these mitochondrial TCA cycle and anaplerotic enzymes (Heusel et al.,
285 2019). Examination of pair-wise correlation between all proteins (**Fig. 4d**) and transcripts (**Extended**
286 **data Fig. 7f**) in these pathways suggests that TCA cycle and anaplerotic enzymes have a positive
287 correlation with each other, which is not altered in MMUT deficiency, unless MMUT is included in
288 the comparison. Overall, the above findings suggest that disruption of MMUT RNA and protein
289 expression drives regulatory changes in certain TCA and anaplerotic enzymes.

290



291

292

Fig. 4: Transcript-protein and protein-protein correlation analysis reveals coordinated

293

relationships between MMUT and TCA genes and proteins but not their isoforms. a, Circos plot

294

depicting raw fold changes of transcripts and proteins, effects sizes derived from differential

295

expression analysis, transcript-protein correlations, and correlative relationships of the MMUT protein

296

to TCA proteins and their corresponding isoforms. **b,** Histograms of Spearman correlations across

297

4318 transcript-protein pairs (left), and 221 samples (right). **c,** Scatter plot of Spearman correlations in

298

MMUT-deficient against control. Euclidean distance from the diagonal is calculated based on the

299

formula $|(\text{MMUT def. correlation} - \text{control correlation})|/\sqrt{2}$. **d,** Chord plot depicting all protein-

300

protein correlations of TCA and related proteins; color code as in (a) indicates the correlation

301

coefficient.

302

303 Metabolomics suggest rewiring of TCA cycle anaplerosis

304

To examine the functional consequences of the above RNA and protein expression changes, we

305

performed untargeted polar metabolomic analysis on a selection of 6 MMUT-deficient and 6 control

306

fibroblast cell lines (for selection criteria, see **Extended data Fig. 8a** and **Methods**). Among the most

307 strongly changed metabolites we found decreased glutamine and alanine as well as increased hexoses,
308 2-methylcitrate, oxo-adipate and amino-adipate. Pyruvate was also significantly accumulated in
309 MMUT-deficient samples (**Fig. 5a**). Combining these alterations with observed changes in RNA and
310 protein expression in the same samples provides insight into how TCA cycle anaplerosis is disrupted
311 in MMUT-deficiency (**Fig. 5b**).

312 The increased pyruvate level (**Fig. 5a, c**), increased expression of the PDH complex inhibitor *PDK4*
313 (**Fig. 3g**), and strongly elevated 2-methylcitrate (**Fig. 5c**), a biomarker of MMA formed by citrate
314 synthase mediated mis-condensation of oxaloacetate with propionyl-CoA instead of acetyl-CoA,
315 together suggest reduced incorporation of pyruvate into the TCA cycle. This is further supported by
316 the analysis of our cross-dimensional data which identified stronger pyruvate to *PDHB* transcript and
317 pyruvate to PDHX protein correlations (**Fig. 5d**), implying reduced pyruvate turnover per transcript
318 and protein respectively. Consecutive metabolites in a pathway often correlate strongly (Williams et
319 al., 2016), here exemplified by malate and fumarate (**Fig. 5d**). Although we found such a correlation
320 between pyruvate and its downstream metabolite (iso)citrate in both control and MMUT-deficient
321 cells, the right shift of MMUT-deficient cells suggests that a higher concentration of pyruvate is
322 required to create the same amount of (iso)citrate as controls (**Fig. 5d**), again supporting reduced
323 incorporation of pyruvate into the TCA cycle.


324 Despite this reduced pyruvate mediated anaplerosis, 2-oxoglutarate, succinate, fumarate and malate
325 levels remained unchanged in MMUT-deficient cells (**Fig. 5c** and **Extended data Fig. 8b**),
326 suggesting overall TCA cycling is stably maintained. We reasoned this may be due to an increase
327 from alternate anaplerotic sources, particularly glutaminolysis. Glutamine strongly correlated with
328 glutamate in both MMUT-deficient and control samples (**Fig. 5d**). However, in MMUT-deficient
329 cells, glutamine and glutamate were decreased (**Fig. 5c**), and there was a negative correlation of
330 glutamate with 2-oxoglutarate, suggestive of more tightly regulated glutamine flux under disease
331 conditions (**Fig. 5d**). Abrogated positive correlation of glutamate and aspartate potentially points to an
332 increased dependence on glutamate for TCA cycling but not production of cataplerotic metabolites
333 (**Fig. 5d**). In line with this, we found an inverse relationship between *MMUT* transcript and 2-

334 oxoglutarate in MMUT-deficient cells (**Fig. 5d**). As a further consequence, we found increased
335 oxoadipate and aminoadipate (**Fig. 5a**), upstream metabolites of 2-oxoadipate dehydrogenase which
336 shares its E2 (DLST) and E3 (DLD) components with 2-oxoglutarate dehydrogenase (**Fig. 5e**),
337 suggestive of a preference for 2-oxoglutarate over 2-oxoadipate metabolism.

338 These results point to an increased reliance on the glutamine anaplerotic pathway in disease; a
339 hypothesis we tested by assessing relative anaplerotic glutamine flux into the TCA cycle using MS-
340 based stable isotope tracing. For this experiment, control, MMUT-KO and DLST-KO 293T cells,
341 validated by Western blotting and enzyme activity measurements (**Extended data Fig. 9**) were
342 cultured in glutamine-free glucose-DMEM supplemented with 4 mM [$^{13}\text{C}_5$]glutamine for 4 hours. It is
343 expected that (M+5) [$^{13}\text{C}_5$]glutamine entering the TCA cycle through (M+5) glutamate and 2-
344 oxoglutarate undergoing oxidative metabolism would generate (M+4) succinate, fumarate, malate,
345 aspartate, citrate and aconitate; while reductive carboxylation would generate in (M+5) aconitate and
346 citrate, as well as (M+3) aspartate, malate, fumarate and succinate (**Fig. 5f**) (Chen et al., 2018).

347 Therefore, by determining the abundance of ^{13}C enrichment and isotopologue distribution we can
348 quantify the glutamine-glutamate-oxoglutarate flux into the TCA cycle and the relative contribution to
349 oxidative metabolism versus reductive carboxylation. Labeled glutamine was equally incorporated
350 into glutamate (**Extended data Fig. 8c**) and subsequently 2-oxoglutarate (**Fig. 5g**) in all three cell
351 lines, suggesting a glutamine-derived anaplerotic flux independent of the genetic defect. Consistent
352 with loss of oxoglutarate dehydrogenase activity, glutamine-derived flux was almost exclusively
353 directed towards the reductive TCA pathway in the DLST-KO cells, indicated most prominently by
354 increased fractional incorporation of M+3 fumarate and decreased M+4 fumarate, aspartate, and
355 citrate (**Fig. 5g, h**); culminating in reduced M+3/M+4 fumarate and aspartate and M+5/M+4 citrate.
356 MMUT deficiency, by contrast, led to slight increase of oxidative TCA cycle flux compared to
357 control, signified by increased fractional incorporation of M+4 citrate (**Fig. 5h**) resulting in a clearly
358 increased M+4/M+5 citrate ratio (**Fig. 5i**). In sum, we found preferred oxidative utilization of
359 anaplerotic glutamine potentially compensating for the lack of succinyl-CoA in MMUT deficiency.

360



361

362 **Fig. 5: Polar metabolomics in selected patient fibroblasts and glutamine flux in**
 363 **CRISPR-KO HEK293 cells highlight increased glutamine anaplerosis. a,** Volcano plot depicting
 364 differentially expressed metabolites. Highlighted are the ones particularly relevant to this study. **b,**
 365 Schematic depiction of the TCA cycle and relevant anaplerotic reactions. The color code indicates
 366 dysregulations on metabolite and protein level; grey metabolites were not detected. **c,** Boxplots to

367 compare relevant TCA cycle metabolites, including the pathologically relevant biomarker 2-
368 methylcitrate formed upon condensation of oxaloacetate with propionyl-CoA; p-values calculated by
369 Wilcoxon rank test. **d**, Pearson correlation of a certain key metabolite against a metabolite, transcript,
370 or protein variable. **e**, Levels of metabolites involved in the two enzymatic steps catalyzed by two
371 oxoacid dehydrogenase complexes (OGDC and OADC) and their proximal reactions. **f**, Schematic
372 representation of labeling of TCA cycle and associated metabolites derived from glutamine
373 anaplerosis. **g**, Enrichment of specific isotopologues of interest. **h**, All detected isotopologues of
374 citrate. **i**, Ratios of isotopologue as indicated by the y-axis label of specific metabolites of interest; p-
375 values are calculated by pairwise t-test.

376


377 MMUT physically interacts with 2-oxoglutarate dehydrogenase and other
378 anaplerotic enzymes

379 The strong protein expression correlation between MMUT and proximal TCA cycle and anaplerotic
380 enzymes (**Fig. 4** and **Extended data Fig. 7**) suggested they may be part of a shared protein complex
381 (Heusel et al., 2019). To gain insights into this potential physical relationship, we took advantage of
382 over-expression of C-terminally flag-tagged versions of MMUT, two pathway members (MMAB and
383 MCEE) expected to participate in any multi-protein complex containing MMUT, and two negative
384 controls (empty vector and VLCAD) in 293T cells (**Fig. 6a**). Using cross-linking affinity purification
385 coupled to mass spectrometry, at 1.0% FDR using 2 peptides minimum at 95% threshold, each of
386 these ‘bait’ proteins pulled-down a total of 100-350 different ‘prey’ proteins over 3 biological
387 replicates (**Fig. 6b**). Within this intersection, we identified 57 prey proteins pulled-down by MMUT,
388 MMAB and MCEE in at least one replicate, but not by empty vector or VLCAD in any replicate (**Fig.**
389 **6b**).

390 Analysis of variance (ANOVA) of the biological triplicates comparing MMUT with EV and VLCAD
391 identified 22 proteins to be significantly enriched (nominal p-value < 0.05) in the MMUT sample
392 (**Fig. 6c** and **Extended data Table 2**). All proteins were designated by Uniprot to have mitochondrial

393 localization, and included GLUD1, GOT2 and DLST (**Fig. 6c**). ANOVA comparing the intersection
 394 of proteins confidently pulled-down by MMUT, MMAB and MCEE but not EV or VLCACD
 395 identified 11 uniquely interacting proteins, including GLUD1 and GOT2; while the intersection of
 396 two of MMUT, MMAB and MCEE against both negative controls identified 13 uniquely interacting
 397 proteins, including DLST (**Fig. 6d** and **Extended data Table 2**). Interaction of MMUT and DLST
 398 was further confirmed by Western blot analysis (**Fig. 6e**). These data indicate that MMUT physically
 399 interacts with GLUD1 and the oxoglutarate dehydrogenase component DLST and suggests that
 400 disruption of this interaction may underlie their altered regulation in disease.

401



402

403 **Figure 6. MMUT interacts physically with GLUD1, DLST, and GOT2 as demonstrated by**
404 **FLAG-tag pull-down. a**, Outline of experimental and control groups indicating which protein was
405 used with a FLAG-tag in a cross-linking affinity purification experiment coupled to subsequent
406 analysis of the pull-down samples by mass spectrometry. **b**, Venn diagram of number of proteins
407 pulled down by the different flag-tagged proteins. **c**, ANOVA p-values of all proteins pulled down by
408 MMUT. Blue dots indicate proteins with mitochondrial location according to Uniprot. **d**, Interaction
409 network of significantly enriched proteins (ANOVA p-value < 0.05). Thicker connector indicates
410 lower p-value. **e**, Western blot of immunoprecipitation of flag-tagged MMUT probing for DLST.
411

412 **Discussion**

413 In this study, we used an integrated multi-omics approach to diagnose and uncover new
414 pathomechanisms of the inborn error of metabolism MMA. Unique to this investigation was the
415 relatively large (for a rare disease) set of patient samples along with corresponding phenotypes
416 available, and the ability to coordinate aliquots from the same samples to generate molecular data at
417 three data layers. Nevertheless, this approach can be generalizable in any setting of inborn monogenic
418 diseases where a large enough biobank exists.

419 Our findings reinforce the value of using complementary datasets to increase diagnostic yield
420 compared to WGS alone. Key to our total diagnostic yield of 84% was additional transcriptomic and
421 biochemical analysis beyond WGS alone. Likewise, integrating multi-omics data layers with
422 phenotypic information enabled sample stratification by disease severity and identification of multi-
423 level alterations which were not apparent following examination of single omics layers. Such a move
424 away from “data silos” into true integrative multi-layered analysis remains challenging, as it requires
425 new analytical and statistical methods to combine these disparate data sets (Karczewski and Snyder,
426 2018). In this capacity, multi-omics factor analysis (Argelaguet et al., 2018) provided indication of
427 disruption to RNA and proteins of TCA cycle and related pathways, a finding verified by the
428 integration of phenotypic data utilizing both PI+ and a clinical severity score. Further overlaying
429 metabolomic data provided indication of specific disturbance of glutamate dehydrogenase and
430 oxoglutarate dehydrogenase, two proteins we found to physically interact with MMUT. Such
431 orthogonal approaches, incorporating not only multi-omics layers, but also clinical information and
432 complementary (experimental) information types, are invaluable for target validation.

433 Our findings highlight the importance of the loss of methylmalonyl-CoA as an anaplerotic source and
434 point to oxoglutarate produced from glutamate as an alternative entry point into the TCA cycle. The
435 rewiring of anaplerosis, potentially as a compensation mechanism, presents a novel therapeutic target
436 for MMA. Such anaplerotic stimulating approaches have precedent in IEMs, including application of
437 triheptanoin in long-chain fatty acid oxidation disorders (Vockley et al., 2021). Unfortunately, since
438 fatty acid β -oxidation produces two acetyl-CoA and one propionyl-CoA per heptanoate molecule, use

439 of this particular compound in MMUT deficiency is not feasible. However, anaplerotic treatment of
440 patients suffering from the MMA-related disorder propionic aciduria with the TCA cycle intermediate
441 citrate has been attempted, with inconsistent results (Longo et al., 2017). Based on our findings,
442 compounds such as dimethyl oxoglutarate, a membrane permeable alternative to 2-oxoglutarate,
443 previously used in a model of OXPHOS dysfunction (Chen et al., 2018), may represent a more
444 promising therapeutic strategy. Studies to delineate the efficacy of such approaches in preclinical and
445 clinical models will be important for the ongoing development of new treatments.

446

447 **Acknowledgements**

448 This project was funded by the ETH domain strategic focus area “Personalized Health and Related
449 Technology” (PHRT; <https://www.sfa-phrt.ch>). This work received financial support from the Swiss
450 National Science Foundation [31003A_175779] to M.R.B. and [310030_192505] to D.S.F. and from
451 the University Research Priority Program of the University of Zurich (URPP) ITINERARE—
452 Innovative Therapies in Rare Diseases. P.F. was supported by the Filling the Gap grant awarded by
453 the Medical Faculty, University of Zurich, Switzerland. We acknowledge the Functional Genomics
454 Center Zurich of the University of Zurich for RNA sequencing of the mouse brain tissues and
455 bioinformatics support as well as for support with the glutamine isotope studies.

456

457 **Author Contributions**

458 Conceptualization, I.X., D.V.M., R.A., G.R., E.D., B.W., M.R.B., D.S.F.; Methodology, P.F., X.B.,
459 D.L., W.S., T.P., M.F., L.S., R.J.M., S.C., S.G., A.v.D., K.H., P.P., N.Z.; Investigation, P.F., X.B.,
460 D.L., W.S., T.P., C.F., A.B., S.C., P.P., F.T., N.Z., G.R., D.S.F.; Writing – Original Draft, P.F.,
461 D.S.F.; Writing – Review & Editing, all co-authors; Visualization, P.F., X.B., D.L., W.S., C.F.;
462 Supervision, P.F., K.H., P.P., F.T., I.X., G.R., E.D., B.W., D.S.F.; Project Administration, P.F.,
463 D.V.M., B.W.; Funding Acquisition, D.V.M., R.A., B.W., M.R.B., D.S.F.

464

465 **Declaration of interests**

466 The authors declare no competing interests.

467

468 **Extended data**

469 Supplementary figures and table in separate file.

470

471 **Methods**

472 Cohort and patient-derived fibroblast samples

473 Primary fibroblast samples and corresponding disease related information, including clinical and
474 diagnostic data, was collected from 1989 to 2015. The information was obtained and used under the
475 ethics approval granted by the Ethics Committee of the Canton of Zurich, Switzerland (no. KEK-
476 2014-0211, amendment: PB_2020-00053). Upon collection, primary fibroblasts were cultured using
477 Dulbecco's modified Eagle medium (Gibco, Life Technologies, Zug, Switzerland) with 10% fetal
478 bovine serum (Gibco) and antibiotics (GE Healthcare, Little Chalfont, UK) and either used
479 immediately, or exchanged to 90% fetal bovine serum and 10% dimethylsulfoxide and stored in
480 cryovials under liquid nitrogen. A frozen aliquot of each fibroblast line was sent for WGS, RNA-seq
481 and DIA-MS analysis (**Fig. 1a**). RNA-seq and DIA-MS were always performed from matched
482 aliquots.

483 Clinical disease severity score

484 The clinical disease severity score was based on five typical clinical signs/symptoms of MMA (Forny
485 et al., 2021), including age at disease onset, as well as presence of neurological abnormalities, kidney
486 impairment, hematological abnormalities, and failure to thrive. Each patient was assigned a score
487 from 0-5 indicating increasing disease severity.

488 Biochemical assays

489 Propionate incorporation into acid precipitable material of primary fibroblasts was assessed according
490 to a protocol described previously (Willard et al., 1976) with modification as described (Froese and

491 Baumgartner, 2020). Methylmalonyl-CoA mutase enzyme activity assay was performed in crude cell
492 lysates as originally described (Baumgartner, 1983; Causey and Bartlett, 1984) using recent
493 modifications (Forny et al., 2014).

494 Whole genome sequencing

495 Genomic DNA was isolated using the QIAmp DNA Mini Kit reagents (Qiagen; Hilden, Germany)
496 following the protocol provided by the supplier. DNA was quantified by Qubit (Thermo Fisher;
497 Waltham, USA). Whole genome sequencing libraries were prepared with the TruSeq DNA PCR-free
498 library reagents (Illumina; San Diego, USA) using 1ug of genomic DNA following the protocol
499 provided by the supplier. The genomic DNA libraries were quantified using the KAPA Library
500 Quantification Complete Kit (Roche; Basel, Switzerland) according to the protocol supplied with the
501 reagents. The quantified libraries were sequenced on the NovaSeq 6000 sequencer (Illumina) using a
502 150-nucleotide paired end run configuration following the protocol provided by the supplier.

503 RNA sequencing

504 Total RNA was isolated using the RNeasy Plus Mini Kit (Qiagen). The total RNA was quantified
505 using the Qubit (Thermo Fisher) and quality-controlled using the Fragment Analyzer (Agilent, Santa
506 Clara, USA). RNA-seq libraries were prepared using the TruSeq Stranded mRNA-seq reagents
507 (Illumina) using 200ng of total RNA following the protocol provided by the supplier. The quality of
508 the RNA-seq libraries was assessed on Fragment Analyzer (Agilent) and the libraries were quantified
509 using the Qubit (Thermo Fisher). The libraries were sequenced on Illumina HiSeq 4000 using the 75-
510 nucleotide paired end run configuration following the protocol provided by the supplier.

511 Sample preparation for mass spectrometry proteotyping measurements

512 Samples were processed in blocks of 8 taking into consideration a balance between disease types and
513 control samples. All other factors within a block were randomized. 230 samples were processed in
514 three batches. For sample processing, aliquots of primary fibroblast (~1e6 cells per vial, frozen in

515 either DMEM or FBS or a mix of DMEM/FBS, plus 10% DMSO) were washed twice in ice-cold PBS
516 (Gibco). After centrifugation for 5 minutes at 300g, the cells were resuspended in lysis buffer
517 (Preomics) at a ratio of 1:1 (vol pellet/vol lysis buffer) and incubated at 95°C for 10 mins. Samples
518 were sonicated in a vial tweeter (Hielscher Ultrasound Technology) at 4°C for 3 cycles with an
519 amplitude 100%, power 80% during 30 secs. For each sample, the total protein concentration was
520 estimated by nanodrop. 100 ug of protein lysate were further processed with the iST kit (Preomics).
521 The purified peptides were resuspended in LCLoad buffer containing iRT peptides (Biognosys) at a
522 concentration of 1 ug/ul.

523 Spectral library generation

524 For spectral library generation, three times 24 samples (3x8 sample blocks) were pooled. Pooled
525 sample batches were digested as described above. 100 µg of purified peptides were fractionated on a
526 C18 column (YMC-Triart, C18, 3µm, 250 x 0.5 mm ID) according to pH on an Agilent HPLC 1260
527 system with a stepped 61 min gradient ranging from 95 % buffer A (20 mM ammonium formate
528 acid/H₂O) to 85% buffer B (20 mM ammonium formate/90 % ACN). 48 fractions were collected per
529 sample and subsequently pooled to 24 fractions. Samples were resuspended in 5% ACN/0.1% FA and
530 analyzed on a QExactive HF-X mass spectrometer (Thermo Fisher Scientific) in DDA mode. The
531 same nLC 1200 configuration and mobile phase gradient elution conditions as for DIA were applied.
532 Full MS survey scans were acquired at a resolution of 60,000 with automatic gain control (AGC)
533 target of 3e6 and a maximum injection time of 45 ms over a scan range of m/z 375-1500. A data-
534 dependent top 12 method was used for HCD MS/MS with a normalized collision energy of 28 at a
535 resolution of 15,000 and a fixed first mass of m/z 100. Precursor ions were isolated in a 1.4-Th
536 window and accumulated to reach an AGC target value of 1e5 with a maximum injection time of 22
537 ms. Precursor ions with a charge state of 1 and 6 as well as isotopes were excluded for fragmentation.
538 Dynamic exclusion was set to 15s.

539 DDA raw files were processed with Proteome Discoverer (v. 2.2) using a human UniProt database
540 (release 201804) together with iRT peptides (Biognosys) and common contaminants. The processing

541 workflow consisted of SequestHT (Eng et al., 1994) and Amanda (Dorfer et al., 2014) nodes coupled
542 with Percolator (Brosch et al., 2009). The following search parameters were used for protein
543 identification: (i) a peptide mass tolerance of 10 ppm; (ii) an MS/MS mass tolerance of 0.02 Da; (iii)
544 fully tryptic peptide search with up to two missed cleavages were allowed; (iv) carbamidomethylation
545 of cysteine was set as fixed modification, methionine oxidation and protein N-term acetylation were
546 set as variable modifications. Percolator was set at max delta Cn 0.05, with target FDR strict 0.01 and
547 target FDR relaxed 0.05. The spectral library from Proteome Discoverer was imported into
548 Spectronaut v12 (Biognosys, Schlieren, Switzerland) using standard parameters with 0.01 peptide
549 spectrum match (PSM) FDR.

550 DIA-MS setup and data analysis

551 For DIA analysis samples were measured on a Q Exactive HF mass spectrometer (Thermo Fisher
552 Scientific). Mobile phase A consisted of HPLC-grade water with 0.1% (v/v) formic acid, and mobile
553 phase B consisted of HPLC-grade ACN with 20% (v/v) HPLC-grade water and 0.1% (v/v) formic
554 acid. Peptide separation was carried out on an ES806, 2 μm , 100 \AA , 150 μm i.d. x 150 mm, C18
555 EASY-Spray column (Thermo Fisher Scientific) at a temperature of 50°C. For LC-MS/MS analyses,
556 2 μg of each sample were loaded onto the column via an Easy-nLC 1200 system (Thermo Fisher
557 Scientific). Samples were loaded at 4 $\mu\text{L}/\text{min}$ with 100% mobile phase A for 5 min. Peptide elution
558 was performed using the following gradient: i) 2% to 8% mobile phase B in 4 min, ii) 8% to 32%
559 mobile phase B in 49 min, iii) 32% to 60 % mobile phase B in 1 min, and iv) ramp to 98% mobile
560 phase B in 1 min at 2 $\mu\text{L}/\text{min}$.

561 For DIA-Acquisition on a Q Exactive HF mass spectrometer, we applied a DIA method published
562 elsewhere (Xuan et al., 2020). In short, we performed an MS1 scan over a mass range of m/z 400-
563 1210 at a resolution of 120,000 with an AGC target value of 3e6 and with a maximum injection time
564 of 50 ms. For MS/MS scans, resolution was at 0,000 with an AGC target value of 1e6 and with
565 “Auto” maximum injection time. Precursor ions were isolated within a 15-Th window and fragmented

566 by HCD with normalized collision energy 28. 54 MS/MS scan windows were defined, interspersed
567 every 18 scans with an MS1 scan.

568 DIA data Analysis was performed in Spectronaut v12 (Biognosys) using standard parameters. For
569 identification, a Qvalue cut-off of 0.01 was applied on the precursor as well as on the protein level.

570 The MS1 area was selected for quantification. Quantification parameters were set to mean peptide
571 quantity for major group quantity, the top 3 peptides were selected for protein quantity calculation.

572 Data filtering was set to Qvalue sparse, with no imputation. Cross-run normalization was set to local

573 Fibroblast cell line selection for polar metabolomics

574 We devised a model of OGDH and GLUD1 expression based on the differential expression method
575 described earlier (Lamparter et al., 2017) and selected the top ten ranked MMUT deficient (MMA014,

576 MMA92, MMA042, MMA67, MMA93, MMA104, MMA013, MMA030, MMA138, MMA036) and

577 the last 10 ranked control cell lines (MMA219, MMA221, MMA227, MMA222, MMA213,

578 MMA230, MMA226, MMA228, MMA225, MMA215). They were cultured as described above. Four

579 cell lines in each group did not meet growth criteria, most likely due to the long freezing period, and

580 were excluded. Six cell lines per group were selected for the polar metabolomics experiment.

581 Fibroblast sample preparation for polar metabolomics

582 100,000 cells per well were seeded in a 6 well plate and grown for 48 hours. Media was removed and

583 cells washed with 2 mL per well of 150 mM ammonium hydrogen carbonate (NH_4HCO_3) at pH 7.4

584 twice. The whole plate was flash frozen in liquid nitrogen for 20 seconds and then stored at -80°C .

585 Metabolites were extracted by putting the plate on dry ice and adding 400 ul of cold (-20°C) 40:40:20

586 acetonitrile:methanol:water and incubate at -20°C for 10 minutes. Supernatant was collected. Added

587 another 400 ul of 40:40:20 acetonitrile:methanol:water and incubated at -20°C for 10 minutes. Plates

588 were put on dry ice and cells were scraped mechanically. The supernatant including the scraped cells

589 were collected in the same tube as during the first extraction step. Collection tubes were centrifuged at

590 13,000 rpm for 2 minutes at 4°C . Supernatants were stored at -20°C prior to metabolomics analysis.

591 Polar metabolomics in patient-derived fibroblasts

592 Metabolomics experiments were performed as previously published (Fuhrer et al., 2011).

593 Mouse care and handling

594 Ethics approval was obtained prior to the study from the Cantonal Veterinary Office Zurich under the
595 license number 202/2014. Mice were kept under standard conditions, i.e. single-ventilated cages with
596 controlled humidity and room temperature of 22°C. Generation of the *Mmut*-p.Met698Lys variant
597 model and crossing with a *Mmut*-ko/wt model was done as previously described (Forny et al., 2016).

598 Harvesting of mouse tissues

599 Urine was collected in the morning after one night in a metabolic cage. The sediment was removed,
600 and supernatant was flash frozen in liquid nitrogen. Tissue samples were harvested from mice aged 58
601 to 63 days. Animals were anesthetized by sevoflurane. Portal blood was taken and kept on ice to
602 coagulate, centrifuged at 4°C and snap frozen in liquid nitrogen directly after. Liver, kidneys, heart,
603 and brain were harvested and snap-frozen in liquid nitrogen. After the procedure, the mice were
604 directly euthanized by cervical dislocation. All samples were stored at -80°C prior to analysis.

605 Metabolomics in mouse tissues

606 The mouse body fluid and tissue samples were prepared as previously published (Want et al., 2013).
607 Sample analysis using liquid chromatography-mass spectrometry was performed as previously
608 published (Abela et al., 2017). Ions were annotated to metabolites based on exact mass to the KEGG
609 database (Kanehisa et al., 2017) considering [M-H⁺] and 0.01 Da mass accuracy. Significantly
610 changing ions between mutant and control conditions were identified using a two-sample t-test.
611 Pathway analysis was performed using annotated ion list ranked by p-value significance. Pathway
612 enrichment were calculated using KEGG metabolic pathway definitions and a hypergeometric test.

613 Transcriptomics in mouse brains

614 Brain tissue samples were harvested as described above. Four females were used per genotype group,
615 which were *Mmut*-ki/wt and *Mmut*-ko/ki. RNA was purified using DNase kit (Qiagen, No. 79254)
616 together with QIAmp RNA Blood Mini Kit (Qiagen, No. 52304). RNA-seq reads were aligned with
617 the STAR-aligner (Dobin et al., 2013). As reference we used the Ensembl mouse genome build
618 GRCm38. Gene expression values were computed with the function `featureCounts` from the R
619 package `Rsubread` (Liao et al., 2013).

620 CRISPR gene-editing experiments

621 CRISPR-Cas9 editing was performed as described (Ran et al., 2013). Cas9 protein was provided as a
622 plasmid (PX459-V2.0, Addgene, 62988) and guide RNA as gBLOCKS (Arbab et al., 2015) (IDT
623 Technologies). HEK293T cells were transfected using the Neon transfection system (Thermo Fisher
624 Scientific) containing 100,000 cells, 0.6 µg of Cas9 plasmid and 600 ng of guide RNA following
625 manufacturer's instructions. 48 h after transfection, cells were collected, diluted to 1 cell/100 µl and
626 transferred to a 96-well plate at 100 µl/well for clonal selection. Correct clones were confirmed by
627 Sanger sequencing of genomic DNA.

628 Western blotting

629 Lysates of HEK293 cell lines were mixed with RIPA lysis buffer and 4X Laemmli buffer to obtain a
630 concentration of 1 µg/µl protein. Samples were incubated at 96°C for 5 minutes. 20 µl of each sample
631 was loaded onto a 10% SDS page gel. Proteins were separated by electrophoresis, transferred with a
632 semi-dry method onto a nitrocellulose membrane (Whatman, GE Healthcare), blocked at room
633 temperature for 2 hours with buffer A (5% skimmed milk, 1.2% w/v Tris-base, 9% w/v NaCl, 0.2%
634 Tween 20, pH 7.6), incubated with primary antibodies dissolved in buffer A overnight at 4°C, and
635 detected using secondary antibodies in buffer A. Primary antibodies used were probing for the
636 following proteins: MMUT (Abcam, ab67869, 1:1000, host: mouse), OGDH (Atlas antibodies,
637 HPA020347, 1:500, host: rabbit), GLUD (Abcam, ab166618, 1:2000, host: rabbit), Beta-actin (Sigma,

638 A1978, 1:5000, host: mouse). Secondary antibodies used were Anti-rabbit HRP (Santa Cruz, sc-2357,
639 1:5000, host: mouse), Anti-mouse HRP (Santa Cruz, sc-516102, 1:5000, host: goat).

640 OGDH and GLUD1 enzyme activity assays

641 Assays in all the HEK293 cell clones for assessment of enzymatic activity of glutamate
642 dehydrogenase (Sigma-Aldrich, St. Louis, USA, catalogue number MAK099) and oxoglutarate
643 dehydrogenase (Sigma-Aldrich, St. Louis, USA, catalogue number MAK189) using the plate reader
644 Victor Nivo by PerkinElmer.

645 Glutamine tracing studies

646 HEK 293T cells were cultured on coverslips in DMEM (Gibco, catalog number: 11960044) without
647 L-glutamine, sodium pyruvate and HEPES supplemented with 10% FBS, 1% antibiotic-antimycotic
648 (Gibco) and [¹³C₅]glutamine (final concentration 4 mM) (Sigma-Aldrich, catalog number: 605166) for
649 4 hours. Medium was then removed, coverslips were quickly dipped into sterile double-distilled water
650 at 37°C and quenched in 80% methanol at -80°C. Cells were scrapped in methanol, collected, and
651 centrifuged at 15'000 g for 15 minutes at 4°C. Supernatants were collected, snap frozen in liquid
652 nitrogen, and stored at -80°C prior to LC/MS analysis. Samples were normalized based on protein
653 content. Volume extracts equivalent to 4 µg protein were dried under a nitrogen stream, reconstituted
654 in 20 µl water (MS grade) and incubated on shaker (800 rpm, 15°C, 10 min). Then, 80 µl injection
655 buffer (90% acetonitrile, 8.8% methanol, 50 mM ammonium acetate) were added, vortexed and
656 centrifuged (10,000 × g, 4°C, 10 min). A total of 50 µl of the supernatant was transferred to a glass
657 vial with narrowed bottom (Total Recovery Vials, Waters, Milford, MA, USA) for LC-MS/MS
658 injection. In addition, quality control (QC) standards, and pooled samples were prepared in the same
659 way to serve as QC for the measurements. Metabolites were separated on a nanoAcquity UPLC
660 (Waters, Milford, MA, USA) equipped with a BEH Amide capillary column (150 µm × 100 mm, 1.7
661 µm particle size, Waters, Milford, MA, USA). The injection volume was 1 µl. Bisolvent system were
662 5 mM ammonium acetate in water (A) and 5 mM ammonium acetate in 95% acetonitrile (B). The

663 flow rate was adjusted over the gradient from 3 to 2 μ l/min. Gradient started with 5% A and increased
664 to 50% A over 13 min. The following 5 min conditions were kept at 50% B, followed by 7 min
665 reequilibration to 5% A. The UPLC was coupled to QExactive mass spectrometer (Thermo) by a
666 Picoview nanoESI source (NewObjectives Inc.). MS data was acquired using negative polarization
667 and all ion fragmentation (AIF). Full scan MS spectra were acquired in profile mode from 70-1050
668 m/z with an automatic gain control target of 1e6, an Orbitrap resolution of 70`000, and a maximum
669 injection time of 200 ms. AIF spectra were acquired with the same setting and fragmented with a
670 normalized collision energy of 35. Generated fragment ions were scanned in the linear trap. Data sets
671 were evaluated with Skyline 21.2. Compounds were identified based mass error and retention time
672 properties observed on references run along with the samples.

673 Affinity capture mass spectrometry

674 293T cells (ATCC #CRL-3216; Manassas, WV) were grown in Dulbecco's Modified Eagle Medium
675 (Gibco, Carlsbad, CA) supplemented with 10% fetal bovine serum (Gibco) and antibiotics (GE
676 Healthcare). Transient transfection of pCDNA3-C-Flag-LIC constructs was performed using
677 Lipofectamine 3000 (Thermo Fisher Scientific) according to manufacturer's instructions. 48 h after
678 transfection, cells were crosslinked using 0.5% paraformaldehyde (PFA, Sigma-Aldrich) in PBS
679 (Gibco) for 10 min at RT, the reaction was quenched with 1.25 M glycine/PBS (Sigma-Aldrich) for
680 10 min at 4°C, cells were centrifuged for 5 min at 2,000 \times g at 4°C, and the pellet resuspended in lysis
681 buffer (1% Nonidet P-40, 0.5% deoxycholine, 150 mM NaCl, 50 mM Tris-HCl, pH7.5, all Sigma-
682 Aldrich). Pre-cleared cell extracts were immunoprecipitated with anti-flag M2 (F3165, Sigma-
683 Aldrich) using Dynabeads Protein G (Thermo Fisher Scientific) according to manufacturer's
684 instructions. Following washing, peptides were released by trypsin (100 ng/ μ l in 10 mM HCl) and
685 supernatants collected, dried, dissolved in 0.1% formic acid and analysed using LC-MS/MS (Orbitrap,
686 Thermo Fisher Scientific). Database searches were performed using Mascot (Matrix Science).

687 Data analysis

688 Data analysis was performed using R version 4.1.0. For the global data layer inspection we used the
689 MOFA package version 1.3.1 (Argelaguet et al., 2018), the MASS package version 7.3-54 (Venables
690 and Ripley, 2002), the fgsea package version 1.18.0 (Korotkevich et al., 2021). Gene enrichment
691 analysis was performed using gene sets downloaded from [http://www.gsea-
692 msigdb.org/gsea/msigdb/index.jsp](http://www.gsea-
692 msigdb.org/gsea/msigdb/index.jsp) “MSigDB Collections” on 28 December 2020. Circos including
693 chord plots were created using the circlize package version 0.4.13 (Gu et al., 2014). The Uniprot
694 portal was accessed on 24 February 2021 at 4 PM to scrape protein localization data. The code for all
695 the analyses and generation of figures is hosted on a repository on the GitHub platform under
696 https://github.com/pforny/mma_pf.

697

698 **References**

- 699 Abela, L., Spiegel, R., Crowther, L.M., Klein, A., Steindl, K., Papuc, S.M., Joset, P., Zehavi, Y.,
700 Rauch, A., Plecko, B., et al. (2017). Plasma metabolomics reveals a diagnostic metabolic fingerprint
701 for mitochondrial aconitase (ACO2) deficiency. *PLoS One* *12*, e0176363.
- 702 Arbab, M., Srinivasan, S., Hashimoto, T., Geijsen, N., and Sherwood, R.I. (2015). Cloning-free
703 CRISPR. *Stem Cell Reports* *5*, 908–917.
- 704 Argelaguet, R., Velten, B., Arnol, D., Dietrich, S., Zenz, T., Marioni, J.C., Buettner, F., Huber, W.,
705 and Stegle, O. (2018). Multi-Omics Factor Analysis—a framework for unsupervised integration of
706 multi-omics data sets. *Mol Syst Biol* *14*, e8124.
- 707 Argmann, C.A., Houten, S.M., Zhu, J., and Schadt, E.E. (2016). A Next Generation Multiscale View
708 of Inborn Errors of Metabolism. *Cell Metab* *23*, 13–26.
- 709 Baumgartner, R. (1983). Activity of the cobalamin-dependent methylmalonyl-CoA mutase. The
710 Cobalamins: Methods in Hematology. Churchill Livingstone, Edinburgh, New York 181–195.
- 711 Brechtmann, F., Mertes, C., Matusėvičiūtė, A., Yépez, V.A., Avsec, Ž., Herzog, M., Bader, D.M.,
712 Prokisch, H., and Gagneur, J. (2018). OUTRIDER: A Statistical Method for Detecting Aberrantly
713 Expressed Genes in RNA Sequencing Data. *The American Journal of Human Genetics* *103*, 907–917.
- 714 Brosch, M., Yu, L., Hubbard, T., and Choudhary, J. (2009). Accurate and sensitive peptide
715 identification with Mascot Percolator. *J Proteome Res* *8*, 3176–3181.
- 716 Causey, A.G., and Bartlett, K. (1984). A radio-HPLC assay for the measurement of methylmalonyl-
717 CoA mutase. *Clinica Chimica Acta* *139*, 179–186.
- 718 Chen, Q., Kirk, K., Shurubor, Y.I., Zhao, D., Arreguin, A.J., Shahi, I., Valsecchi, F., Primiano, G.,
719 Calder, E.L., Carelli, V., et al. (2018). Rewiring of Glutamine Metabolism Is a Bioenergetic
720 Adaptation of Human Cells with Mitochondrial DNA Mutations. *Cell Metabolism* *27*, 1007-1025.e5.
- 721 Cummings, B.B., Marshall, J.L., Tukiainen, T., Lek, M., Donkervoort, S., Foley, A.R., Bolduc, V.,
722 Waddell, L.B., Sandaradura, S.A., O’Grady, G.L., et al. (2017). Improving genetic diagnosis in
723 Mendelian disease with transcriptome sequencing. *Sci Transl Med* *9*, eaal5209.
- 724 Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and
725 Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* *29*, 15–21.
- 726 Dorfer, V., Pichler, P., Stranzl, T., Stadlmann, J., Taus, T., Winkler, S., and Mechtler, K. (2014). MS
727 Amanda, a universal identification algorithm optimized for high accuracy tandem mass spectra. *J*
728 *Proteome Res* *13*, 3679–3684.
- 729 Eng, J.K., McCormack, A.L., and Yates, J.R. (1994). An approach to correlate tandem mass spectral
730 data of peptides with amino acid sequences in a protein database. *J Am Soc Mass Spectrom* *5*, 976–
731 989.
- 732 Ferreira, C.R., Rahman, S., Keller, M., and Zschocke, J. (2021). An international classification of
733 inherited metabolic disorders (ICIMD). *Journal of Inherited Metabolic Disease* *44*, 164–177.
- 734 Forny, P., Froese, D.S., Suormala, T., Yue, W.W., and Baumgartner, M.R. (2014). Functional
735 characterization and categorization of missense mutations that cause methylmalonyl-CoA mutase
736 (MUT) deficiency. *Hum Mutat* *35*, 1449–1458.

- 737 Forny, P., Schumann, A., Mustedanagic, M., Mathis, D., Wulf, M.-A., Nägele, N., Langhans, C.-D.,
738 Zhakupova, A., Heeren, J., Scheja, L., et al. (2016). Novel Mouse Models of Methylmalonic Aciduria
739 Recapitulate Phenotypic Traits with a Genetic Dosage Effect. *J Biol Chem* *291*, 20563–20573.
- 740 Forny, P., Hörster, F., Ballhausen, D., Chakrapani, A., Chapman, K.A., Dionisi-Vici, C., Dixon, M.,
741 Grünert, S.C., Grunewald, S., Haliloglu, G., et al. (2021). Guidelines for the diagnosis and
742 management of methylmalonic acidemia and propionic acidemia: First revision. *Journal of*
743 *Inherited Metabolic Disease* *44*, 566–592.
- 744 Frésard, L., Smail, C., Ferraro, N.M., Teran, N.A., Li, X., Smith, K.S., Bonner, D., Kernohan, K.D.,
745 Marwaha, S., Zappala, Z., et al. (2019). Identification of rare-disease genes using blood transcriptome
746 sequencing and large control cohorts. *Nat Med* *25*, 911–919.
- 747 Froese, S., and Baumgartner, M.R. (2020). Lysosomal Vitamin B12 Trafficking. In *Ion and Molecule*
748 *Transport in Lysosomes*, (CRC Press), p.
- 749 Fuhrer, T., Heer, D., Begemann, B., and Zamboni, N. (2011). High-throughput, accurate mass
750 metabolome profiling of cellular extracts by flow injection-time-of-flight mass spectrometry. *Anal*
751 *Chem* *83*, 7074–7080.
- 752 Garrod, Archibald E. (1908). The Croonian Lectures ON INBORN ERRORS OF METABOLISM.
753 *The Lancet* *172*, 1–7.
- 754 Gonorazky, H.D., Naumenko, S., Ramani, A.K., Nelakuditi, V., Mashouri, P., Wang, P., Kao, D.,
755 Ohri, K., Viththiyapaskaran, S., Tarnopolsky, M.A., et al. (2019). Expanding the Boundaries of RNA
756 Sequencing as a Diagnostic Tool for Rare Mendelian Disease. *Am J Hum Genet* *104*, 466–483.
- 757 Gu, Z., Gu, L., Eils, R., Schlesner, M., and Brors, B. (2014). circlize Implements and enhances
758 circular visualization in R. *Bioinformatics* *30*, 2811–2812.
- 759 Heusel, M., Bludau, I., Rosenberger, G., Hafen, R., Frank, M., Banaei-Esfahani, A., van Drogen, A.,
760 Collins, B.C., Gstaiger, M., and Aebersold, R. (2019). Complex-centric proteome profiling by SEC-
761 SWATH-MS. *Mol Syst Biol* *15*, e8438.
- 762 Hirano, M., Emmanuele, V., and Quinzii, C.M. (2018). Emerging therapies for mitochondrial
763 diseases. *Essays Biochem* *62*, 467–481.
- 764 Hörster, F., Garbade, S.F., Zwickler, T., Aydin, H.I., Bodamer, O.A., Burlina, A.B., Das, A.M., De
765 Klerk, J.B.C., Dionisi-Vici, C., Geb, S., et al. (2009). Prediction of outcome in isolated methylmalonic
766 acidurias: combined use of clinical and biochemical parameters. *Journal of Inherited Metabolic*
767 *Disease* *32*, 630.
- 768 Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., and Morishima, K. (2017). KEGG: new
769 perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Res* *45*, D353–D361.
- 770 Karczewski, K.J., and Snyder, M.P. (2018). Integrative omics for health and disease. *Nat Rev Genet*
771 *19*, 299–310.
- 772 Korotkevich, G., Sukhov, V., Budin, N., Shpak, B., Artyomov, M.N., and Sergushichev, A. (2021).
773 Fast gene set enrichment analysis.
- 774 Kremer, L.S., Bader, D.M., Mertes, C., Kopajtich, R., Pichler, G., Iuso, A., Haack, T.B., Graf, E.,
775 Schwarzmayr, T., Terrile, C., et al. (2017). Genetic diagnosis of Mendelian disorders via RNA
776 sequencing. *Nat Commun* *8*, 15824.

- 777 Lamparter, D., Marbach, D., Rueedi, R., Bergmann, S., and Kutalik, Z. (2017). Genome-Wide
778 Association between Transcription Factor Expression and Chromatin Accessibility Reveals
779 Regulators of Chromatin Accessibility. *PLOS Computational Biology* *13*, e1005311.
- 780 Liao, Y., Smyth, G.K., and Shi, W. (2013). The Subread aligner: fast, accurate and scalable read
781 mapping by seed-and-vote. *Nucleic Acids Res* *41*, e108.
- 782 Longo, N., Price, L.B., Gappmaier, E., Cantor, N.L., Ernst, S.L., Bailey, C., and Pasquali, M. (2017).
783 Anaplerotic therapy in propionic acidemia. *Mol Genet Metab* *122*, 51–59.
- 784 McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K.,
785 Altshuler, D., Gabriel, S., Daly, M., et al. (2010). The Genome Analysis Toolkit: a MapReduce
786 framework for analyzing next-generation DNA sequencing data. *Genome Res* *20*, 1297–1303.
- 787 Nusinow, D.P., Szpyt, J., Ghandi, M., Rose, C.M., McDonald, E.R., Kalocsay, M., Jané-Valbuena, J.,
788 Gelfand, E., Schweppe, D.K., Jedrychowski, M., et al. (2020). Quantitative Proteomics of the Cancer
789 Cell Line Encyclopedia. *Cell* *180*, 387–402.e16.
- 790 Palmer, E.E., Sachdev, R., Macintosh, R., Melo, U.S., Mundlos, S., Righetti, S., Kandula, T.,
791 Minoche, A.E., Puttick, C., Gayevskiy, V., et al. (2021). Diagnostic Yield of Whole Genome
792 Sequencing After Nondiagnostic Exome Sequencing or Gene Panel in Developmental and Epileptic
793 Encephalopathies. *Neurology* *96*, e1770–e1782.
- 794 Poplin, R., Chang, P.-C., Alexander, D., Schwartz, S., Colthurst, T., Ku, A., Newburger, D., Dijamco,
795 J., Nguyen, N., Afshar, P.T., et al. (2018). A universal SNP and small-indel variant caller using deep
796 neural networks. *Nat Biotechnol* *36*, 983–987.
- 797 Rahman, S. (2020). Mitochondrial disease in children. *J Intern Med* *287*, 609–633.
- 798 Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013). Genome
799 engineering using the CRISPR-Cas9 system. *Nat Protoc* *8*, 2281–2308.
- 800 Rath, S., Sharma, R., Gupta, R., Ast, T., Chan, C., Durham, T.J., Goodman, R.P., Grabarek, Z., Haas,
801 M.E., Hung, W.H.W., et al. (2021). MitoCarta3.0: an updated mitochondrial proteome now with sub-
802 organelle localization and pathway annotations. *Nucleic Acids Res* *49*, D1541–D1547.
- 803 Schon, K.R., Horvath, R., Wei, W., Calabrese, C., Tucci, A., Ibañez, K., Ratnaike, T., Pitceathly,
804 R.D.S., Bugiardini, E., Quinlivan, R., et al. (2021). Use of whole genome sequencing to determine
805 genetic basis of suspected mitochondrial disorders: cohort study. *BMJ* e066288.
- 806 Venables, W.N., and Ripley, B.D. (2002). *Modern applied statistics with S* (New York: Springer).
- 807 Vockley, J., Burton, B., Berry, G., Longo, N., Phillips, J., Sanchez-Valle, A., Chapman, K.,
808 Tanpaiboon, P., Grunewald, S., Murphy, E., et al. (2021). Effects of triheptanoin (UX007) in patients
809 with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study.
810 *J Inher Metab Dis* *44*, 253–263.
- 811 Want, E.J., Masson, P., Michopoulos, F., Wilson, I.D., Theodoridis, G., Plumb, R.S., Shockcor, J.,
812 Loftus, N., Holmes, E., and Nicholson, J.K. (2013). Global metabolic profiling of animal and human
813 tissues via UPLC-MS. *Nat Protoc* *8*, 17–32.
- 814 Willard, H.F., Ambani, L.M., Hart, A.C., Mahoney, M.J., and Rosenberg, L.E. (1976). Rapid prenatal
815 and postnatal detection of inborn errors of propionate, methylmalonate, and cobalamin metabolism: a
816 sensitive assay using cultured cells. *Hum Genet* *34*, 277–283.

817 Williams, E.G., Wu, Y., Jha, P., Dubuis, S., Blattmann, P., Argmann, C.A., Houten, S.M., Amariuta,
818 T., Wolski, W., Zamboni, N., et al. (2016). Systems proteomics of liver mitochondria function.
819 *Science* 352, aad0189–aad0189.

820 Xuan, Y., Bateman, N.W., Gallien, S., Goetze, S., Zhou, Y., Navarro, P., Hu, M., Parikh, N., Hood,
821 B.L., Conrads, K.A., et al. (2020). Standardization and harmonization of distributed multi-center
822 proteotype analysis supporting precision medicine studies. *Nat Commun* 11, 5248.

823

824